STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMRX
  4. [Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

AMRX EVP exercises options for 131,856 shares at $2.75, then sells

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) reported insider activity by its Executive Vice President. On November 12, 2025, the officer exercised stock options for 36,331 and 95,525 shares at an exercise price of $2.75 per share and sold 131,856 Class A shares at a $11.92 weighted average price.

The sale occurred across multiple trades between $11.85 and $12.02 per share. Following these transactions, the reporting person directly beneficially owned 146,403 shares. The reported option grants (fully vested) show 0 derivative securities remaining after exercise, with prior expirations listed as May 7, 2028 and March 1, 2029.

Positive

  • None.

Negative

  • None.
Insider Shah Nikita
Role Executive Vice President
Sold 131,856 shs ($1.57M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 36,331 $0.00 --
Exercise Stock Option (Right to Buy) 95,525 $0.00 --
Exercise Class A Common Stock 36,331 $2.75 $100K
Exercise Class A Common Stock 95,525 $2.75 $263K
Sale Class A Common Stock 131,856 $11.92 $1.57M
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Class A Common Stock — 182,734 shares (Direct)
Footnotes (1)
  1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This option is fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shah Nikita
(Last) (First) (Middle)
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BLVD.
(Street)
BRIDGEWATER NJ 08807
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 11/12/2025 M 36,331 A $2.75 182,734 D
Class A Common Stock 11/12/2025 M 95,525 A $2.75 278,259 D
Class A Common Stock 11/12/2025 S 131,856 D $11.92(1) 146,403 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.75 11/12/2025 M 36,331 (2) 05/07/2028 Class A Common Stock 36,331 $0 0 D
Stock Option (Right to Buy) $2.75 11/12/2025 M 95,525 (2) 03/01/2029 Class A Common Stock 95,525 $0 0 D
Explanation of Responses:
1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. This option is fully vested.
Remarks:
/s/ Denis Butkovic, Attorney-in-Fact 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AMRX report on this Form 4?

An Executive Vice President exercised options and sold 131,856 Class A shares on November 12, 2025.

How many options were exercised and at what price for AMRX?

Options for 36,331 and 95,525 shares were exercised at $2.75 per share.

At what price were AMRX shares sold by the EVP?

The weighted average sale price was $11.92, with individual trades between $11.85 and $12.02 per share.

How many AMRX shares does the reporting person own after the transactions?

Direct beneficial ownership is 146,403 shares after the reported transactions.

Were the AMRX options fully vested before exercise?

Yes. The filing notes the option grants were fully vested.

What were the expiration dates tied to the exercised AMRX options?

The option grants listed expirations of May 7, 2028 and March 1, 2029.

What role does the reporting person hold at AMRX?

Executive Vice President.